Industrial Alliance Investment Management Inc. Takes $2.90 Million Position in Outset Medical, Inc. (NASDAQ:OM)

Industrial Alliance Investment Management Inc. purchased a new position in Outset Medical, Inc. (NASDAQ:OM – Get Rating) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 182,280 shares of the company’s stock, valued at approximately $2,904,000.

Other institutional investors have also recently made changes to their positions in the company. PDT Partners LLC boosted its stake in shares of Outset Medical by 46.6% in the second quarter. PDT Partners LLC now owns 64,788 shares of the company’s stock worth $963,000 after acquiring an additional 20,600 shares during the last quarter. US Bancorp DE boosted its stake in Outset Medical by 56.6% during the third quarter. US Bancorp DE now owns 4,068 shares of the company’s stock worth $65,000 after buying an additional 1,471 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Outset Medical by 70.1% during the second quarter. JPMorgan Chase & Co. now owns 5,191,427 shares of the company’s stock worth $77,144,000 after buying an additional 2,140,206 shares during the last quarter. PFM Health Sciences LP acquired a new position in Outset Medical during the third quarter worth $11,620,000. Finally, FMR LLC boosted its stake in Outset Medical by 0.8% during the second quarter. FMR LLC now owns 7,169,138 shares of the company’s stock worth $106,533,000 after buying an additional 57,429 shares during the last quarter. 98.84% of the stock is owned by institutional investors and hedge funds.

Outset Medical Stock Performance

NASDAQ OM opened at $20.49 on Friday. The stock’s fifty day moving average is $25.58 and its two-hundred day moving average is $21.09. The firm has a market capitalization of $996.63 million, a P/E ratio of -6.01 and a beta of 1.56. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.20 and a current ratio of 7.19. Outset Medical, Inc. has a fifty-two week low of $11.41 and a fifty-two week high of $48.71.

Outset Medical (NASDAQ:OM – Get Rating) last posted its earnings results on Monday, February 13th. The company reported ($0.86) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.02. Outset Medical had a negative return on equity of 55.22% and a negative net margin of 141.24%. The company had revenue of $32.01 million for the quarter, compared to the consensus estimate of $31.51 million. During the same quarter in the previous year, the business earned ($0.87) earnings per share. On average, research analysts anticipate that Outset Medical, Inc. will post -3.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley boosted their price objective on Outset Medical from $17.00 to $27.00 and gave the stock an “equal weight” rating in a research note on Friday, January 6th.

Insider Buying and Selling at Outset Medical

In other Outset Medical news, COO Martin Vazquez sold 19,500 shares of Outset Medical stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $30.00, for a total value of $585,000.00. Following the sale, the chief operating officer now owns 104,435 shares in the company, valued at $3,133,050. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Martin Vazquez sold 19,500 shares of the business’s stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $30.00, for a total value of $585,000.00. Following the sale, the chief operating officer now owns 104,435 shares in the company, valued at approximately $3,133,050. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Leslie Trigg sold 30,000 shares of the business’s stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $28.06, for a total value of $841,800.00. Following the completion of the sale, the chief executive officer now owns 414,044 shares in the company, valued at approximately $11,618,074.64. The disclosure for this sale can be found here. Insiders have sold 154,002 shares of company stock worth $4,031,759 over the last quarter. 4.00% of the stock is currently owned by company insiders.

Outset Medical Profile

(Get Rating)

Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.